Compare ARQQ & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | LEXX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.6M | 16.3M |
| IPO Year | N/A | N/A |
| Metric | ARQQ | LEXX |
|---|---|---|
| Price | $27.44 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $1.50 |
| AVG Volume (30 Days) | 363.7K | ★ 1.5M |
| Earning Date | 12-09-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $530,000.00 | ★ $705,923.00 |
| Revenue This Year | $1,054.72 | $13.35 |
| Revenue Next Year | $30.00 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $11.00 | $0.46 |
| 52 Week High | $62.00 | $2.38 |
| Indicator | ARQQ | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 42.17 |
| Support Level | $21.43 | $0.46 |
| Resistance Level | $29.20 | $0.72 |
| Average True Range (ATR) | 1.84 | 0.09 |
| MACD | 0.67 | 0.01 |
| Stochastic Oscillator | 70.97 | 84.14 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.